ClinicalTrials.gg
RecruitingNCT07520006Updated Nov 16, 2026

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

A Phase 1/2 interventional study of NX-5948 and venetoclax in B-cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Nurix Therapeutics, Inc.. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nurix Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 16, 2026Site recruiting status changedStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Planned enrollment
55th of 380
150 · median 37
Started
2026
with 20 others
Phase 1/2
75 of 398
20 open now
Primary completion
2033-05
later than 148 of 156 live
Registered
388th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 55th largest by planned enrollment of the 380 interventional ones that give a count, is one of 21 that started in 2026, is one of 75 in phase 1/2, reaches primary completion later than 148 of the 156 other live ones, and was the 388th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Read the detailed description

Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.

The study will look at:

  • How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
  • The effects of bexobrutideg in the body when taken with these other treatments
  • How well bexobrutideg treats CLL or SLL when taken with these other treatments
03

Conditions studied

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Degrader
  • B-cell malignancy
  • BTKi
  • Bexobrutideg
  • Venetoclax
  • Obinutuzumab
  • Rituximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
  • Must sign an form indicating understanding of the study purpose and procedures and willingness to participate

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
  • Use of systemic (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
  • Previously treated with a BTK degrader
  • Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
  • Known central nervous system (CNS) lymphoma or leukemia
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NX-5948 + venetoclax

    Drug: NX-5948 · Drug: venetoclax

  • Experimental
    NX-5948 + venetoclax + rituximab

    Drug: NX-5948 · Drug: venetoclax · Drug: rituximab

  • Experimental
    NX-5948 + venetoclax + obinutuzumab

    Drug: NX-5948 · Drug: venetoclax · Drug: obinutuzumab

Interventions

  • Administered orally once daily as a capsule

    Also known as: bexobrutideg

  • Administered orally once daily as a tablet per prescribing information

  • Administered as an intravenous (IV) infusion per prescribing information

  • Administered as an IV infusion per prescribing information

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events

    Time frame: Up to approximately 7 years

Secondary outcomes

  1. Objective response rate as determined by investigator

    The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR

    Time frame: Up to approximately 7 years

  2. Duration of response as determined by investigator

    Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier

    Time frame: Up to approximately 7 years

  3. Progression-free survival as determined by investigator

    Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier

    Time frame: Up to approximately 7 years

  4. Complete response rate as determined by investigator

    The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL.

    Time frame: Up to approximately 7 years

  5. Time to response as determined by investigator

    Time from the start date of study treatment to the date of the first assessment of a response

    Time frame: Up to approximately 7 years

  6. Overall survival

    Time from the start date of study treatment to the date of death from any cause

    Time frame: Up to approximately 7 years

  7. Pharmacokinetic profile of NX-5948

    NX-5948 concentrations in blood samples

    Time frame: Up to approximately 1 year

  8. Pharmacokinetic profile of venetoclax

    Venetoclax concentrations in blood samples

    Time frame: Up to approximately 1 year

  9. Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)

    Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life

    Time frame: Baseline and up to approximately 27 months

  10. Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)

    Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes

    Time frame: Baseline and up to approximately 27 months

07

Study locations

5 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2033, 80 months after the start.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 80 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Sep 30, 2026was Aug 2026
Primary completionEst.
May 2033
CompletionEst.
May 2033
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • UPMC Hillman Cancer Center · Pittsburgh, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast · Tyler, United StatesNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • University of Kansas Cancer Center · Kansas City, United States
  • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
  • New Jersey Cancer Care · Belleville, United States
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
across 3 updates, Oct 22, 2026 – Nov 16, 2026
Start date
Aug 2026→Sep 30, 2026 (actual)
Oct 22, 2026
Show all 3 updates
  1. Nov 16, 2026
    1 site added
    Show site
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
    + 1 other change: verification date
  2. Nov 3, 2026
    3 sites added
    Show 3 added (3 United States)
    • University of Kansas Cancer Center · Kansas City, United States
    • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
    • New Jersey Cancer Care · Belleville, United States
  3. Oct 22, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • UPMC Hillman Cancer Center · Pittsburgh, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast · Tyler, United StatesNot yet recruiting→Recruiting
    Start date Aug 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07520006
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Sep 30, 2026
Primary completion
May 2033 (estimated)
Completion
May 2033 (estimated)
Last update
Nov 16, 2026

Study contacts

Additional Site Contact Information
Contact
clinicaltrials@nurixtx.com
415-417-3418
Study Director
study director · Nurix Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NX-5948

Start the discussion